drugset / Trial / NCT00283712

Use of Infliximab for the Treatment of Pemphigus Vulgaris

NCT00283712

RandomizedParallel-groupDouble-blindTreatment

Summary

Pemphigus vulgaris (PV) is a rare skin disorder that causes blistering of the skin and mucous membranes. Infliximab is a man-made antibody used to treat certain types of immune system disorders, including rheumatoid arthritis and Crohn's disease. This study will determine if infliximab given in combination with prednisone is a safe and effective treatment for adults with PV.

Timeline

Start
2006-03
Primary completion
2010-12
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 5 mg/kg Intravenous

Indications